Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A registrational phase 3 randomized, double-blind trial of MVA-BN® -RSV Vaccine in China

Next Previous
Trial Profile

A registrational phase 3 randomized, double-blind trial of MVA-BN® -RSV Vaccine in China

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA-BN RSV (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Nuance Pharma

Most Recent Events

  • 22 Jul 2023 Status changed from planning to withdrawn prior to enrolment According to a Nuance Pharma media release.
  • 13 Nov 2022 According to a Nuance Pharma media release, the company is planning to conduct the pivotal Phase III study as an extension of the global MRCT in 2023.
  • 13 Nov 2022 According to a Nuance Pharma media release, the Center for Drug Evaluation (CDE) has approved the IND application supporting the clinical trial in mainland China.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top